These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6683005)

  • 1. Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.
    Mattsson C; Nilsson S; Häggroth L
    Thromb Res; 1983 Apr; 30(1):91-100. PubMed ID: 6683005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
    Topol EJ; Ciuffo AA; Pearson TA; Dillman J; Builder S; Grossbard E; Weisfeldt ML; Bulkley BH
    J Am Coll Cardiol; 1985 Jan; 5(1):85-91. PubMed ID: 4038373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
    Electricwala A; Emeis JJ; Atkinson T
    J Pharmacol Exp Ther; 1986 Jul; 238(1):254-8. PubMed ID: 2425075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
    Martin H; Auel H; Riedel C
    Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.
    Agnelli G; Buchanan MR; Fernandez F; Boneu B; Van Ryn J; Hirsh J; Collen D
    Circulation; 1985 Jul; 72(1):178-82. PubMed ID: 4039986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
    Páramo JA; Collen D
    Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits.
    Agnelli G; Buchanan MR; Fernandez F; Van Ryn J; Hirsh J
    Blood; 1985 Aug; 66(2):399-401. PubMed ID: 4040410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
    Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
    Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.
    Korninger C; Stassen JM; Collen D
    Thromb Haemost; 1981 Oct; 46(3):658-61. PubMed ID: 7198302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory control of fibrinolytic therapy].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):30-7. PubMed ID: 2427412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Position and developmental trends in fibrinolytic therapy].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological potentials for activating the fibrinolytic system].
    Markwardt F
    Z Gesamte Inn Med; 1984 May; 39(10):209-13. PubMed ID: 6380126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.